Intravenous Sodium Diuril®
(chlorothiazide sodium for injection)

• Sodium Diuril is a diuretic and antihypertensive.
• Sodium Diuril is a dry, sterile lyophilized powder supplied in vials equivalent to 0.5g of chlorothiazide.

__________________________________________________________________________________

Indications and Usage
Intravenous Sodium DIURIL® (chlorothiazide sodium) is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.

DIURIL has also been found useful in edema due to various forms of renal dysfunction such as nephritic syndrome, acute glomerulonephritis, and chronic renal failure.

Important Safety Information
DIURIL is contraindicated in patients with anuria and a hypersensitivity to any component of this product or to other sulfonamide-derived drugs.  Use in infants and children is generally not recommended and should be used during pregnancy only if clearly needed. Use with caution in patients with severe renal disease.  Consider withholding or discontinuing diuretic therapy if renal disease progresses.  Sensitivity reactions may occur.  Exacerbation or activation of systemic lupus erythematosus has been reported.  Lithium should not be given with diuretics.  Observe patients for evidence of fluid or electrolyte imbalance while on DIURIL.  Chloride replacement may be required in the treatment of metabolic alkalosis.  Periodic serum electrolyte assessments should be done at appropriate intervals.  Hypokalemia, dilutional hyponatremia as well as hyperuricemia, acute gout, and hyperglycemia may develop.  Diabetic patients may require insulin or oral hypoglycemia agent adjustment.  Antihypertensive effects of DIURIL may be enhanced in postsympathectomy patients.  Hypermagnesemia and decreased urinary calcium excretion may occur.  DIURIL may increase cholesterol and triglyceride levels.  DIURIL may interact with alcohol, barbiturates, narcotics, antidiabetic drugs, other antihypertensive drugs, corticosteroids, ACTH, pressor amines, skeletal muscle relaxants, lithium and NSAIDS.  DIURIL should be discontinued before testing for parathyroid function.

The following adverse reactions have been reported:  weakness, hypotension, pancreatitis, jaundice, diarrhea, cramping, constipation, gastric irritation, nausea, anorexia, aplastic anemia, thrombocytopenia, anaphylactic reactions, respiratory distress, photosensitivity, fever, rash, electrolyte imbalance, hyperglycemia, muscle spasm, vertigo, restlessness, erythema multiforme, exfoliative dermatitis, transient blurred vision, renal dysfunction, interstitial nephritis, hematuria, and impotence.  Whenever adverse reactions are moderate or severe, DIURIL therapy should be reduced or withdrawn.

For more information, please see Full Prescribing Information.

® Registered trademark of Merck, Sharp & Dohme, a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ 08889, U.S.A.